Safety and efficacy of durvalumab with R-CHOP or R
International journal of hematology
washington; seattle; swedish cancer; Diffuse large B-cell lymphoma; Durvalumab; High risk; R-CHOP
Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated durvalumab, a programmed death-ligand 1 inhibitor, combined with R-CHOP or lenalidomide + R-CHOP (R
Nowakowski, Grzegorz S; Willenbacher, Wolfgang; Greil, Richard; Larsen, Thomas S; Patel, Krish; Jäger, Ulrich; Manges, Robert F; Trümper, Lorenz; Everaus, Hele; Kalakonda, Nagesh; Brown, Peter; Jørgensen, Judit Meszaros; Cunningham, David; Dell'Aringa, Justine; Fox, Brian; Rubio, Neus Domper; Kilavuz, Nurgul; Casadebaig, Marie-Laure; Manzke, Oliver; and Munoz, Javier, "Safety and efficacy of durvalumab with R-CHOP or R" (2021). Articles, Abstracts, and Reports. 5506.